Dinoprostone for Cervical Ripening: Contraindications and Management in Cardiovascular Patients

Absolute Contraindications

Active cardiovascular disease is an absolute contraindication to dinoprostone because it can cause marked blood‑pressure changes, potential coronary vasospasm, and a low but real risk of arrhythmias. 1
Cyanotic heart disease is an absolute contraindication, as dinoprostone may reduce systemic vascular resistance and worsen hemodynamics. 1

In women with active cardiovascular disease or cyanosis, mechanical cervical ripening methods (e.g., Foley catheter) are preferred over any pharmacologic agent. 1
When a prior uterine surgery (e.g., cesarean delivery) is present, mechanical methods are also favored to minimize uterine rupture risk. 1

Prior to dinoprostone use, all patients should be screened for active cardiovascular disease, prior uterine surgery, and cyanotic conditions. 1
Continuous fetal heart‑rate and uterine‑activity monitoring should be instituted throughout dinoprostone administration to promptly detect tachysystole, hyperstimulation, or fetal distress. (Implied from guideline context; citation pertains to the need for alternative methods when contraindications exist.) 1

If the cervix remains unfavorable after an appropriate course of dinoprostone, clinicians should transition to a mechanical method or consider cesarean delivery rather than continuing pharmacologic ripening. 1
Prolonged induction attempts in the presence of an unfavorable cervix should be avoided to reduce maternal and fetal risk. 1
When dinoprostone ripening fails, the recommended next step is to switch to a mechanical method (e.g., Foley catheter) or proceed to operative delivery, rather than repeating dinoprostone. 1

Women identified as high‑risk (including those with cardiac disease, complex medical conditions, or anticipated complications) should deliver in tertiary centers with multidisciplinary specialist teams. 1

The American College of Obstetricians and Gynecologists recommends dinoprostone gel for labor induction in pregnant women at or near term with a medical or obstetrical indication for induction and an unfavorable cervix (Bishop score <5), provided there is no active cardiovascular disease, prior cesarean delivery, or other absolute contraindications 2
Dinoprostone gel is specifically indicated for use when the Bishop score is <5 (unfavorable cervix), as cervical ripening is required before oxytocin can be effective 3, 4, 2
The European Society of Cardiology notes that active cardiovascular disease is a contraindication for dinoprostone use due to its profound blood pressure effects and theoretical risk of coronary vasospasm and arrhythmias 5, 2, 6

The American College of Obstetricians and Gynecologists recommends assessing the Bishop score first to determine cervical favorability before administering dinoprostone gel 5, 2
Continuous fetal heart rate monitoring and uterine activity monitoring are mandatory during dinoprostone gel administration 2

Dinoprostone gel should be administered as a single 10 mg vaginal insert that releases approximately 0.3 mg/hour, and removed after 12 hours maximum or upon onset of active labor, whichever comes first 2
The American College of Obstetricians and Gynecologists recommends waiting at least 30 minutes after removing the dinoprostone insert before starting oxytocin 7

Oral misoprostol (20-25 µg every 2-6 hours) results in fewer cesarean sections (RR 0.84) and costs significantly less than dinoprostone gel 2, 6
The choice between dinoprostone gel and oral misoprostol depends on contraindications and institutional protocols, but both are inferior to mechanical methods in women with prior cesarean delivery 2, 7